Matthew Gavidia

Brindley Brooks, who founded HS Connect (HSconnect.org), a patient advocacy group for those affected with hidradenitis suppurativa (HS), discussed step edits and other barriers to treatment caused by insurance requirements in the management of HS.

Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis Biotherapeutics, discusses the need for increased research and awareness on intertriginous disease in psoriasis.

Despite decreasing trends observed in the global burden of alopecia areata, low-income countries and ​​Western Sub-Saharan Africa regions continue to exhibit rising incidence and disability-adjusted life-years rates.

Most patients with atopic dermatitis had flunctuating levels of depressive symptoms, with having public or no insurance, more severe itch, and skin pain cited as additional predictors of adverse mental health outcomes.

Freezing of gait incidence among patients with Parkinson disease (PD) was associated with older age, more severe motor symptoms, postural instability/gait difficulty clinical phenotype, and other risk factors.

Treatment of hepatitis C virus (HCV) with direct-acting antiviral medications was associated with low HCV reinfection rates among patients who inject drugs, although risk for reinfection was highest in the first 24 weeks of treatment and among those with ongoing injecting drug use.

European adult patients with atopic dermatitis most valued therapies that had rapid onset, oral administration, and were able to be paused—even at the expense of reduced efficacy.

Patients with Parkinson disease (PD) exhibited significant improvement in measurement scales for depression and anxiety when treated with subthalamic nucleus deep brain stimulation.

Brindley Brooks, who founded HS Connect (HSconnect.org), a patient advocacy group for those affected with hidradenitis suppurativa (HS), spoke on the need for awareness among physicians and patients on the clinical features of HS in regard to both physical and psychosocial burdens.

US cases of monkeypox have risen to 6600, and Thursday's declaration aims to provide enhanced testing, treatment, and vaccine capabilities nationwide.

A review explores critical factors for dermatologists to consider in managing the physical and behavioral care needs of LGBTQIA patients with hidradenitis suppurativa.

Proton pump inhibitor use was cited as the only avoidable risk factor for mortality in patients with Clostridioides difficile infection.

Substantially impaired quality of life was shown in patients with photoaggravated atopic dermatitis, with phototesting cited as an effective diagnostic approach in promoting personalized care.

Significantly more patients with Parkinson disease (PD) achieved improved motor function and clinical outcomes when treated with high- vs low-dose inhaled levodopa.

Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis Biotherapeutics, speaks about disease manifestations, comorbidities, and other factors to consider in the management of psoriasis.

Systemic corticosteroids were more commonly prescribed vs other systemic drug options in Germany for patients with atopic dermatitis (AD) despite their unfavorable risk-benefit profile, with a substantial economic burden cited among these populations.

Faster motor and cognitive progression of Parkinson disease was found in patients with higher baseline cerebrospinal fluid neurofilament heavy levels.

Each additional hour of care per day provided by registered nurses to Medicare beneficiaries admitted to an acute care hospital with a sepsis diagnosis was associated with a 3% decreased risk of 60-day mortality.

An increased risk of developing myocardial infarction was observed among patients with hidradenitis suppurativa (HS), whereas risk of cerebrovascular accident and peripheral vascular disease was comparable between those with HS and controls.

Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis Biotherapeutics, discussed key factors associated with poor behavioral health issues and quality of life among patients with psoriasis.

Elaine Siegfried, MD, professor of pediatrics and dermatology, Saint Louis University Health Sciences Center, speaks on step edits and other barriers limiting access to biologic, topical, and other medications for the treatment of atopic dermatitis (AD).

Angiotensin receptor blockers exhibited potential neuroprotective properties for reducing Parkinson disease (PD) risk in patients with newly diagnosed hypertension.

Patients who experienced Clostridioides difficile infection had increased risks of mortality and hospital readmission, as well as greater length of stay and total hospital charges.

Increased atopic dermatitis severity in pediatric patients was associated with a greater physical, emotional, social, and economic impact on families.

Stakeholders from Horizon Blue Cross Blue Shield of New Jersey discuss new ways to address management gaps for chronic behavioral health conditions, including a new integrated care model that puts community behavioral health providers in charge of overall care.

Ruxolitinib (Opzelura) cream is the first and only FDA-approved treatment for repigmentation in patients with vitiligo.

Patrick Burnett, MD, PhD, FAAD, chief medical officer of Arcutis Biotherapeutics, discusses findings of a recent survey exploring the emotional burden of plaque psoriasis and unmet needs related to current topical treatments.

Hospital ward cleaning with potassium peroxymonosulphate-based environmental disinfectant and a decrease in days of therapy with carbapenems were associated with a reduction in the rate of hospital-onset Clostridioides difficile infection.

A significant decline in HIV-related service utilization was observed among at-risk populations in India during the COVID-19 pandemic.

The risk of wound-related issues was approximately 2-fold in adult patients with hidradenitis suppurativa (HS) undergoing total hip/knee arthroplasty vs those without HS.